Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease NEW YORK and MELBOURNE, Australia, June 8, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results from the Company's Phase 2 trial in patients with diabetic...

Mesoblast Cell Therapy Reduces Inflammation And Reverses Coronary Artery Dysfunction In Rheumatoid Arthritis Preclinical Study NEW YORK, May 12, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC:MBLTY) today announced publication of results in the May issue of the peer-reviewed journal PLOS One showing that its...

Rafarma (RAFA) Enters $50,000,000 Ceftriaxone Market and Signs Long-Term National and Regional Distribution Contracts SANDY, Utah, June 6, 2013 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. (the "Company") (Pink Sheets:RAFA) announces commencement of production of the antibiotic Ceftriaxone. Ceftriaxone treats...